Medical Research News
PRESS RELEASE ARCHIVES FROM SEND2PRESS® NEWSWIRE
NOTICE: THIS IS ARCHIVAL CONTENT AND LIKELY OUT OF DATE.
Edited for Send2Press by Carly Zander
Health Discovery Corporation Announces Agreement with Stanford University for Biomarker and Pathway Discovery in Lymphatic Insufficiency
SAVANNAH, GA - March 22, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board:
HDVY) today announced the signing of an Agreement with Stanford University to use Health Discovery
Corporations proprietary and patent protected Fractal Genomics Modeling (FGM) techniques to identify new
patterns of biomarkers in lymphatic insufficiency and its response to therapeutic lymphangiogenesis.
According to the Agreement, ownership of Research Program Inventions conceived, discovered or reduced to
practice under the Research Program will be determined based on inventorship. As such, any invention
discovered using our analytical tools on this Stanford database will be jointly owned by Health Discovery
Corporation and Stanford.
Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of Health Discovery Corporation stated,
"It is an honor that Stanford will be working with our Company to utilize our unique approach to systems
biology to discover new patterns of biomarkers and pathways associated with lymphatic insufficiency."
According to the World Health Organization, lymphedema affects 250 million people worldwide. Others
estimate that one in every twenty-five will suffer from some form of lymphedema during their lifetime.
The M.D. Anderson Cancer Center in Houston, Texas reports that approximately 15% of all women with breast
cancer will develop lymphedema over the course of their lifetime and that lymphedema resulting from
prostate cancer is on the rise.
Health Discovery Corporation is a systems biology oriented biomarker and pathway discovery company, which
uses proprietary advanced mathematical platforms, such as Fractal Genomics Modeling (FGM) techniques, to
help identify and characterize diagnostic targets and therapeutic candidates. Focusing on disease vs.
normal, within complex genomic, proteomic and clinical data sets, Health Discovery Corporation was
established to provide pharmaceutical and diagnostic companies with a broad range of analytical and
decision support solutions to accelerate effective diagnostic and drug discovery. Founded in September
2003, the Company has offices in Texas, Georgia, and California. For more information contact Robert S.
Braswell IV of Health Discovery Corporation +1-866-953-9031.
Organization Website: www.healthdiscoverycorp.com
Source of News:
Health Discovery Corporation
Find More Stock Info, Charts, News on OTC BB: HDVY
Yahoo!® Finance (HDVY.OB)
Previous News from Health Discovery Corporation (HDVY)
FOR INFORMATION ABOUT THE COMPANY OR ORGANIZATION(S) MENTIONED IN THE ABOVE BUSINESS NEWS ARTICLE, PLEASE CONTACT THE COMPANY DIRECTLY AND NOT THIS WEBSITE.
DISCLAIMER: the above business news article is believed accurate but not guaranteed, and is based on business news supplied by the company or organization mentioned and/or quoted in the story. The organization providing the news to Send2Press is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements and public companies should be thoroughly researched before considering material investment. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article.
USE OF THE ABOVE NEWS ARTICLE
Article is Copr. © 2004 Neotrope/Send2Press. Reproduction of this news article in any form requires written authorization. You may freely link to this article. For more information on using this article in print or on your website, please visit: